As of 2025-07-09, the Intrinsic Value of Krebs Biochemicals and Industries Ltd (KREBSBIO.NS) is (202.67) INR. This KREBSBIO.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 86.00 INR, the upside of Krebs Biochemicals and Industries Ltd is -335.70%.
The range of the Intrinsic Value is (280.50) - (173.44) INR
Based on its market price of 86.00 INR and our intrinsic valuation, Krebs Biochemicals and Industries Ltd (KREBSBIO.NS) is overvalued by 335.70%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (280.50) - (173.44) | (202.67) | -335.7% |
| DCF (Growth 10y) | (167.95) - (248.25) | (190.34) | -321.3% |
| DCF (EBITDA 5y) | (137.69) - (152.91) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (147.78) - (163.38) | (1,234.50) | -123450.0% |
| Fair Value | -62.48 - -62.48 | -62.48 | -172.65% |
| P/E | (164.68) - (232.91) | (215.85) | -351.0% |
| EV/EBITDA | (130.24) - (147.78) | (137.05) | -259.4% |
| EPV | (120.13) - (130.02) | (125.07) | -245.4% |
| DDM - Stable | (51.34) - (123.92) | (87.63) | -201.9% |
| DDM - Multi | (29.63) - (60.31) | (40.21) | -146.8% |
| Market Cap (mil) | 1,854.16 |
| Beta | 1.32 |
| Outstanding shares (mil) | 21.56 |
| Enterprise Value (mil) | 3,974.83 |
| Market risk premium | 8.31% |
| Cost of Equity | 17.05% |
| Cost of Debt | 5.70% |
| WACC | 10.44% |